Read More

Viracta Therapeutics Announces Final Phase 1b/2 Data; Says Shows Durable Signal Of Efficacy For Nana-val In Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma In Oral Presentation At ASH 2021 Meeting

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021 SAN

VIRX